Black Diamond Therapeutics (BDTX)
(Delayed Data from NSDQ)
$2.89 USD
+0.15 (5.47%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $2.90 +0.01 (0.35%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Price, Consensus and EPS Surprise
BDTX 2.89 +0.15(5.47%)
Will BDTX be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for BDTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BDTX
All You Need to Know About Black Diamond (BDTX) Rating Upgrade to Buy
Should You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings?
BDTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Black Diamond (BDTX) is on the Move, Here's Why the Trend Could be Sustainable
Does Black Diamond (BDTX) Have the Potential to Rally 152.96% as Wall Street Analysts Expect?
Black Diamond (BDTX) Upgraded to Buy: What Does It Mean for the Stock?
Other News for BDTX
Analysts Are Bullish on These Healthcare Stocks: Black Diamond Therapeutics (BDTX), MiNK Therapeutics (INKT)
Black Diamond Therapeutics (BDTX) Receives a Buy from Wedbush
TD Cowen Keeps Their Buy Rating on Black Diamond Therapeutics (BDTX)
3 Best Stocks to Buy Now, 10/8/2024, According to Top Analysts
Black Diamond Therapeutics (BDTX) Gets a Buy from Piper Sandler